Tea Pemovska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tea Pemovska has a total of 422 co-authors. Here are the top co-authors by number of shared publications:
- Krister Wennerberg
Biotech Research and Innovation Center, University of Copenhagen, Copenhagen, Denmark
16 shared publications - Berend Snijder
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich
14 shared publications - Gregory Ian Vladimer
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
14 shared publications - Tim Heinemann
Technische Universität Braunschweig
13 shared publications - Olli Kallioniemi
Institute for Molecular Medicine Finland-FIMM, Helsinki Institute for Life Sciences-HiLIFE, University of Helsinki, Finland
12 shared publications - Giulio Superti-Furga
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
11 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by Wiley in HemaSphere
- Vol. 10 (4) , e70345
Preclinical models of hepatosplenic γδ T‐cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib
- 16 April 2026
- Published by Wiley in HemaSphere
- Vol. 10 (4) , e70345
Open AccessPreclinical models of hepatosplenic γδ T‐cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib
- Open Access
- 9 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression
T-prolymphocytic leukemia (T-PLL) typically presents with rapidly progressing tumor burden. However, 15–25% of cases are diagnosed at an indolent stage with asymptomatic and stable low-level blood lymphocytosis over up to 2-3 years before advancing to active-stage disease. To define the molecular changes underlying this transition, we perform single-cell RNA sequencing of 28 treatment-naïve samples including 11 longitudinally acquired indolent/active pairs, paralleled by longitudinal whole genome sequencing. This reveals both patient-specific lesions and common global alterations of gene expression. Strong upregulations of MYC-target gene signatures in active T-PLL samples associated with enhanced energy metabolism implicate acquired autonomy from energetic restrictions. Recurrent downregulation of genes of the T-cell-receptor signaling cascade and reduced interactions of the T-PLL cell with non-leukemic cell types further indicate progressive independence from regulatory survival signals and escape from micromilieu-mediated control. This single-cell and disease-stage resolved genomic analysis of T-PLL provides insights into shared mechanisms of tumor evolution, which have to prove their amenability as targetable lesions.
- 9 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSingle-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression
T-prolymphocytic leukemia (T-PLL) typically presents with rapidly progressing tumor burden. However, 15–25% of cases are diagnosed at an indolent stage with asymptomatic and stable low-level blood lymphocytosis over up to 2-3 years before advancing to active-stage disease. To define the molecular changes underlying this transition, we perform single-cell RNA sequencing of 28 treatment-naïve samples including 11 longitudinally acquired indolent/active pairs, paralleled by longitudinal whole genome sequencing. This reveals both patient-specific lesions and common global alterations of gene expression. Strong upregulations of MYC-target gene signatures in active T-PLL samples associated with enhanced energy metabolism implicate acquired autonomy from energetic restrictions. Recurrent downregulation of genes of the T-cell-receptor signaling cascade and reduced interactions of the T-PLL cell with non-leukemic cell types further indicate progressive independence from regulatory survival signals and escape from micromilieu-mediated control. This single-cell and disease-stage resolved genomic analysis of T-PLL provides insights into shared mechanisms of tumor evolution, which have to prove their amenability as targetable lesions.
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Supplementary Data containing the statistical analysis plan, Supplemental Figures 1-6 and Supplemental Tables 1 and 2
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Supplementary Data containing the statistical analysis plan, Supplemental Figures 1-6 and Supplemental Tables 1 and 2
- Open Access
- 30 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 295-309
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery
T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype–specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL. Significance: Integrated and harmonized multiomics analyses and drug screening across a heterogeneous panel of T-cell leukemias and lymphomas provide a resource to uncover drug targets and predictive biomarkers to improve patient outcomes.
- 30 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 295-309
Open AccessMultiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery
T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype–specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL. Significance: Integrated and harmonized multiomics analyses and drug screening across a heterogeneous panel of T-cell leukemias and lymphomas provide a resource to uncover drug targets and predictive biomarkers to improve patient outcomes.
- Open Access
- 24 April 2025
- Published by Wiley in HemaSphere
- Vol. 9 (4) , e70129
Comparing functional and genomic‐based precision medicine in blood cancer patients
Tumor‐agnostic precision medicine (PM) strategies promise to support treatment decisions in relapsed/refractory blood cancer patients. Genomic‐based PM (gPM) and drug screening‐based functional PM (fPM) currently represent the most prominent PM methodologies. In this study, we report the feasibility analysis of the first 55 patients enrolled in the multicentric, randomized controlled EXALT‐2 trial (NCT04470947) comparing treatment recommendations of gPM, fPM, and physicians' choice (PC) head to head. In 54 patients (98%), the diagnostic workflow was successfully implemented, resulting in treatment recommendations for 42 patients (76%), of whom 29 (69%) received the suggested individualized treatments. Actionable targets were identified in 65% by gPM and 80% by fPM (64% microscopy‐based, 86% flow cytometry‐based fPM). The median time to report was shorter for fPM than for gPM testing. The two strategies revealed overlapping drug targets in 60% of cases. Both, gPM and fPM can efficiently be integrated into the clinical routine to guide therapy decisions for the majority of patients.
- 24 April 2025
- Published by Wiley in HemaSphere
- Vol. 9 (4) , e70129
Open AccessComparing functional and genomic‐based precision medicine in blood cancer patients
Tumor‐agnostic precision medicine (PM) strategies promise to support treatment decisions in relapsed/refractory blood cancer patients. Genomic‐based PM (gPM) and drug screening‐based functional PM (fPM) currently represent the most prominent PM methodologies. In this study, we report the feasibility analysis of the first 55 patients enrolled in the multicentric, randomized controlled EXALT‐2 trial (NCT04470947) comparing treatment recommendations of gPM, fPM, and physicians' choice (PC) head to head. In 54 patients (98%), the diagnostic workflow was successfully implemented, resulting in treatment recommendations for 42 patients (76%), of whom 29 (69%) received the suggested individualized treatments. Actionable targets were identified in 65% by gPM and 80% by fPM (64% microscopy‐based, 86% flow cytometry‐based fPM). The median time to report was shorter for fPM than for gPM testing. The two strategies revealed overlapping drug targets in 60% of cases. Both, gPM and fPM can efficiently be integrated into the clinical routine to guide therapy decisions for the majority of patients.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Drug testing in patient biopsy-derived cells can identify potent treatments for patients suffering from relapsed or refractory hematologic cancers. Here we investigate the use of weakly supervised deep learning on cell morphologies (DML) to complement diagnostic marker-based identification of malignant and nonmalignant cells in drug testing. Across 390 biopsies from 289 patients with diverse blood cancers, DML-based drug responses show improved reproducibility and clustering of drugs with the same mode of action. DML does so by adapting to batch effects and by autonomously recognizing disease-associated cell morphologies. In a post hoc analysis of 66 patients, DML-recommended treatments led to improved progression-free survival compared with marker-based recommendations and physician's choice–based treatments. Treatments recommended by both immunofluorescence and DML doubled the fraction of patients achieving exceptional clinical responses. Thus, DML-enhanced ex vivo drug screening is a promising tool in the identification of effective personalized treatments.Significance:We have recently demonstrated that image-based drug screening in patient samples identifies effective treatment options for patients with advanced blood cancers. Here we show that using deep learning to identify malignant and nonmalignant cells by morphology improves such screens. The presented workflow is robust, automatable, and compatible with clinical routine.This article is highlighted in the In This Issue feature, p. 476
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Drug testing in patient biopsy-derived cells can identify potent treatments for patients suffering from relapsed or refractory hematologic cancers. Here we investigate the use of weakly supervised deep learning on cell morphologies (DML) to complement diagnostic marker-based identification of malignant and nonmalignant cells in drug testing. Across 390 biopsies from 289 patients with diverse blood cancers, DML-based drug responses show improved reproducibility and clustering of drugs with the same mode of action. DML does so by adapting to batch effects and by autonomously recognizing disease-associated cell morphologies. In a post hoc analysis of 66 patients, DML-recommended treatments led to improved progression-free survival compared with marker-based recommendations and physician's choice–based treatments. Treatments recommended by both immunofluorescence and DML doubled the fraction of patients achieving exceptional clinical responses. Thus, DML-enhanced ex vivo drug screening is a promising tool in the identification of effective personalized treatments.Significance:We have recently demonstrated that image-based drug screening in patient samples identifies effective treatment options for patients with advanced blood cancers. Here we show that using deep learning to identify malignant and nonmalignant cells by morphology improves such screens. The presented workflow is robust, automatable, and compatible with clinical routine.This article is highlighted in the In This Issue feature, p. 476